myeloablative therapy

myeloablative therapy

Oncology The use of RT and/or high-dose chemotherapy to eliminate tumor load–eg, of myeloma in BM, followed by restitution of native BM with either allogeneic BMT or autologous–self BMT, which is reinfused after purging it of plasma cells, using monoclonal antibodies
Mentioned in ?
References in periodicals archive ?
The presentation described in-depth immune reconstitution data from the completed Phase 1/2, multi-center clinical study of NiCord as a stand-alone graft after myeloablative therapy in patients with high-risk hematologic malignancies.
The oral presentation, "Rapid and Robust CD4+ and CD8+ T-, NK-, B-Cell, Dendritic Cell, and Monocyte Reconstitution after Nicotinamide-Expanded Cord Blood Transplantation" (Abstract 69), described in-depth immune reconstitution data from the completed Phase 1/2, multi-centre clinical study of NiCord as a stand-alone graft after myeloablative therapy in patients with high-risk hematologic malignancies.
The poster presentation, "Rapid and robust CD4+ and CD8+ T-, NK-, B- and monocyte cell reconstitution after nicotinamide-expanded cord blood transplantation", described early, in-depth immune reconstitution data from the completed Phase 1/2, multicenter clinical study of NiCord as a stand-alone graft after myeloablative therapy in patients with high-risk hematologic malignancies.
It will be given to patients aged 12 months and over, whose disease has at least partially responded to first stage chemotherapy, followed by myeloablative therapy and stem cell transplant.
Though originally described in Jamaican children with alkaloid-induced hepatotoxicity, it is most commonly seen in the setting of myeloablative therapy for hematopoietic stem cell transplantation.
She was treated with abdominal tumor resection and 4 cycles of ICE chemotherapy with PBSC support after cycle 3 (an infusion of 0.3 x [10.sup.6] [CD34.sup.+] cells/kg from apheresis that did not collect required dose for myeloablative therapy was given).
Seeger et al., "Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study," Journal of Clinical Oncology, vol.
In addition as prophylaxis during myeloablative therapy the patient also received ciprofloxacin which is also associated with thrombocytopenia.
These patients had previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and autologous stem cell transplantation (ASCT).
The product is intended for the treatment of high-risk neuroblastoma in patients aged 12 months to 17 years, who have earlier received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and autologous stem cell transplantation.
NE was initially described and often seen in paediatric patients of post-chemotherapy neutropenia, as high as 38-46% in paediatric haematologic malignancies usually presenting with intestinal perforation.5 NE is also reported in other conditions associated with bone marrow failure and low white cell counts like aplastic anaemia, myelofibrosis, Myelodysplastic syndrome, bone marrow infiltration, and AIDS.6 The increased usage of upfront myeloablative therapy, standard of care combination polychemotherapy, protracted and prolonged many lines of chemotherapy, and newer drugs may increase the number of cases reported in future.2
(5.) Matthay KK, Reynolds CP, Seeger RC, Shimada H, Adkins ES, Haas-Kogan D, Gerbing RB, London WB, Villablanca JG: Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A children's oncology group study.